U.S. Tariffs on India’s pharma: Who pays, what’s at risk Vivek Seigell, Sr VP, Corporate Affairs, Apeejay Stya Svran Group Aug 12, 2025 The structural answer to tariff risk is not endless cost-cutting; it is moving up the value chain
Industry experts weigh in on US tariff exemption for Indian pharma amid section 232 review EP News Bureau Aug 8, 2025 The US administration has excluded Indian pharma exports from immediate tariff hikes. Industry leaders highlight the importance of…
